drugset / Trial / NCT03835949
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.
Timeline
- Start
- 2019-07-16
- Primary completion
- 2022-06
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Uliledlimab | Monoclonal antibody | — | — |
| Background | Atezolizumab | Monoclonal antibody | — | — |